Executive Summary

The tricuspid valve space is heating up: TriCares has won FDA IDE approval to begin a U.S. study of its Topaz transcatheter tricuspid valve replacement system, while VDyne has received FDA clearance to launch a pivotal trial for its competing tricuspid replacement device — two milestones in a single week that underscore the accelerating race in transcatheter tricuspid therapy. Meanwhile, new research suggests that a simple nutritional score may predict outcomes after TAVR as well as the complex risk calculators surgeons currently rely on, and a study highlights the significant impact of frailty on outcomes after MitraClip procedures. Earnings season approaches, with Edwards Lifesciences and Boston Scientific both reporting April 22.

For the clinical audience: today's digest is dominated by the tricuspid replacement pipeline, where two companies are now positioning for pivotal U.S. data in a space that had zero guideline-level transcatheter recommendations as recently as 2020. The ESC 2025 guidelines gave transcatheter TR treatment a Class IIa recommendation based on TRILUMINATE, Tri.Fr, and TRISCEND II — but those data are largely for edge-to-edge repair, not replacement. Whether TTVR devices like Topaz and VDyne can demonstrate superiority over TEER remains an open and commercially consequential question. On the TAVR front, two converging publications on the Geriatric Nutritional Risk Index (GNRI) make a compelling case for nutritional assessment as a complement to — or simplification of — traditional risk scores. And an intriguing valve-in-valve-in-valve case report reminds us that the lifetime management challenge of transcatheter valves is no longer theoretical.

---

Today's Key Findings

• [NOTABLE] TriCares wins FDA IDE to study Topaz transcatheter tricuspid valve replacement in a U.S. clinical trial — adding another entrant to the increasingly crowded TTVR field alongside Edwards' Evoque (TRISCEND II) and VDyne.
• [NOTABLE] VDyne secures FDA approval to begin its pivotal VISTA-US trial for transcatheter tricuspid valve replacement — now actively enrolling 30 patients.
• GNRI matches EuroSCORE II and STS-PROM for predicting 30-day mortality after TAVR in a 3,470-patient single-center study, with a companion meta-analysis of 9,647 patients confirming low GNRI is associated with 90% higher all-cause mortality.
• Frailty impacts outcomes after mitral TEER — a propensity-matched analysis underscores the importance of patient selection beyond anatomy.
• Valve-in-valve-in-valve case report demonstrates the complexity of lifetime TAVR management, with platform switching from balloon-expandable to self-expanding as a rescue strategy.

---

Aortic Valve (TAVR/TAVI)

Nutritional Status: A Simpler Path to TAVR Risk Stratification?

Two publications today converge on the same message: the Geriatric Nutritional Risk Index (GNRI) — calculable from just five variables (age, height, weight, sex, serum albumin) — may be as good as the EuroSCORE II (21 variables) or STS-PROM (69 variables) at predicting post-TAVR mortality. Boehm et al. analyzed 3,470 consecutive TAVR patients at a single center over 13 years and found no statistical difference in AUC between GNRI and either established score for 30-day mortality (0.72 vs. 0.69 vs. 0.72). Patients in the major GNRI risk group had a hazard ratio of 4.6 for overall mortality. Separately, Liu et al. published a meta-analysis of 13 cohort studies (9,647 patients) confirming that low pre-procedural GNRI was associated with a 90% increase in all-cause mortality after TAVR (HR 1.90, 95% CI: 1.60–2.26).

Editorial note: These findings are clinically intuitive — malnutrition is a well-established marker of frailty — but carry important caveats. The Boehm study is single-center and retrospective, and AUC values in the 0.69–0.72 range represent only moderate discriminative ability for all three scores. The meta-analysis pools heterogeneous studies with variable GNRI cutoffs and follow-up durations. Still, the simplicity of GNRI is appealing. Rather than replacing EuroSCORE II or STS-PROM, GNRI may be most valuable as a complementary flag for nutritional optimization before TAVR — an area where prehabilitation protocols remain inconsistent. The ESC 2025 guidelines emphasize frailty assessment but do not specify nutritional indices; future updates may need to formalize this.

Diastolic Dysfunction: Multi-Omics Reveals Metabolic Roots

Panaou et al. performed untargeted lipidomics (1,110 lipids) and proteomics (834 proteins) on plasma from 231 TAVI patients, finding that 39% had severe diastolic dysfunction. Multi-omic network analysis identified two molecular clusters: one characterized by disrupted mitochondrial membrane phospholipids (cardiolipins) linked to cytoskeletal remodeling, and another featuring elevated acylcarnitines indicative of metabolic dysfunction and inflammation. Patients with severe diastolic dysfunction had more AF, higher NT-proBNP, more HF hospitalizations, and higher mortality.

Editorial note: This is basic science work, but clinically relevant. Diastolic dysfunction remains a major determinant of persistent symptoms and HF hospitalization after TAVR — the "expected benefit didn't materialize" population. If metabolic biomarkers can identify patients unlikely to improve hemodynamically after valve replacement, they could inform the intervention-vs-watchful-waiting decision in asymptomatic severe AS, where the ESC 2025 guidelines now support early intervention (Class IIa) but the ideal patient phenotype remains debated.

Urinary Biomarker for AKI Prediction After TAVI

Obata et al. evaluated urinary liver-type fatty acid-binding protein (L-FABP) measured via point-of-care testing in 186 TAVI patients at a single center. AKI occurred in 12.9% of patients. Preoperative urinary L-FABP showed the best predictive performance (AUC 0.74) and independently predicted AKI after adjustment for ejection fraction and renal dysfunction. This is the first study to apply POCT-based L-FABP measurement in the TAVI setting.

Editorial note: AKI remains an underappreciated complication of TAVR, particularly in patients with CKD who are increasingly being treated. The single-center design and modest sample size limit generalizability, and the AUC of 0.74 suggests room for improvement. However, a point-of-care biomarker that could stratify AKI risk preoperatively has practical appeal for periprocedural management — contrast minimization, hydration protocols, and ICU planning.

Valve-in-Valve-in-Valve: The Lifetime Management Challenge Made Real

Emini et al. report a case of a patient with early failure of two balloon-expandable transcatheter valves who was successfully treated with a third prosthesis — a self-expanding supra-annular valve — in a valve-in-valve-in-valve (ViViV) configuration. The platform switch from balloon-expandable to self-expanding corrected severe transvalvular regurgitation while preserving adequate effective orifice area.

Editorial note: This case, while anecdotal, is a harbinger. As the ESC 2025 guidelines acknowledge, lifetime management planning at the index TAVR procedure is paramount — particularly for patients with life expectancy exceeding assumed valve durability. The ESC explicitly recommends CT-based anatomical analysis to assess future valve-in-valve feasibility, coronary obstruction risk, and sinus sequestration. THV explantation carries 12–17% mortality. This case underscores the importance of commissural alignment and platform selection at the first implant. The recently updated REdo TAVI trial (NCT06557798), now recruiting 550 patients in Leeds comparing redo-TAVI, surgical explant, and conservative management, will provide much-needed prospective data on this growing challenge.

Digital Rehabilitation for TAVR Patients

Jia et al. published a qualitative longitudinal study examining rehabilitation needs and adherence among TAVR patients and caregivers during digital home-based cardiac rehabilitation. Full abstract not available, but the study addresses the growing recognition that post-TAVR recovery extends well beyond the catheterization lab, particularly in elderly patients where frailty and deconditioning are prevalent.

CKM Syndrome and TAVI Outcomes

Ni et al. published a letter in the European Journal of Heart Failure regarding the prevalence and influence of cardiovascular-kidney-metabolic (CKM) syndrome on outcomes after TAVI. While the letter's specific arguments are not available in abstract form, this intersects with the ESC 2025 guidelines' emphasis on comorbidity burden as a driver of post-TAVR outcomes, particularly in the context of futility assessment.

---

Mitral Valve (MitraClip, PASCAL, TMVR)

Frailty and Mitral TEER: Patient Selection Matters

Jain et al. published a propensity-score matched analysis in Catheterization and Cardiovascular Interventions examining the impact of frailty on outcomes following mitral transcatheter edge-to-edge repair. While the full abstract is not available, this study speaks to a critical tension in the field: TEER for secondary MR has been upgraded to Class I in the ESC 2025 guidelines (based on COAPT 5-year follow-up and RESHAPE-HF2), but the COAPT criteria explicitly exclude patients with advanced HF — a population that overlaps substantially with the frail.

Editorial note: The enthusiasm for TEER must be tempered by rigorous patient selection. The COAPT trial's benefit was observed in patients with LVEF 20–50%, LVESD ≤70 mm, and at least one HF hospitalization — but also required patients to tolerate optimization of guideline-directed medical therapy. Frailty indices were not part of the formal COAPT criteria, yet frailty likely explains much of the heterogeneity in real-world TEER outcomes. As the ESC 2025 guidelines now recommend TEER as Class I for ventricular SMR, the field needs validated frailty cutoffs to prevent indication creep into populations unlikely to benefit.

India: Simultaneous TAVI + TMVR

Knocksense reports that Jaipur's Eternal Hospital performed India's first combined TAVI and TMVR procedure. While details are limited, simultaneous multi-valve transcatheter intervention represents a niche but growing frontier — one that challenges heart teams to weigh cumulative procedural risk, contrast load, and vascular access planning against the alternative of staged procedures or surgical correction of both valves.

---

Tricuspid Valve (TriClip, TTVR)

[NOTABLE] TriCares Wins FDA IDE for Topaz Tricuspid Replacement

MassDevice reports that TriCares has received FDA Investigational Device Exemption (IDE) approval to begin a U.S. clinical trial of its Topaz transcatheter tricuspid valve replacement system. This adds another competitor to a tricuspid replacement landscape that already includes Edwards' Evoque (TRISCEND II, now actively not recruiting with 864 enrolled) and VDyne's system (VISTA-US, now recruiting).

[NOTABLE] VDyne Clears FDA for Pivotal Tricuspid Replacement Trial

MedTech Dive reports that VDyne has secured FDA clearance to begin its pivotal VISTA-US trial (NCT05848284) evaluating the VDyne Transcatheter Tricuspid Valve Replacement System in 30 patients with symptomatic severe TR. The trial is now actively recruiting.

Editorial note: The tricuspid replacement space is evolving rapidly, but perspective is needed. The ESC 2025 Class IIa recommendation for transcatheter TR treatment was based primarily on TEER data (TRILUMINATE, Tri.Fr) rather than replacement. TRISCEND II showed superior symptom/QoL improvement for Evoque replacement but flagged higher bleeding and pacemaker rates. Replacement devices face unique challenges in the tricuspid position: the thin-walled right ventricle, variable annular geometry, proximity to conduction tissue, and hepatic venous drainage. Both VDyne (30-patient early feasibility) and TriCares (IDE approval, trial design TBD) are in early stages. The field should resist premature enthusiasm until randomized data against TEER emerge — the "right device for the right patient" question in TR is far from settled.

---

Device & Technology

Non-Fluoroscopic ASD Closure: Radiation-Free Structural Intervention

Chang et al. published the protocol for PANASD, a prospective, multicenter, randomized controlled trial enrolling 660 patients across eight Chinese centers comparing percutaneous and non-fluoroscopic (echocardiography-guided) ASD closure against conventional fluoroscopy-guided procedures. While not directly a valve therapy, this RCT tests a principle — radiation-free structural heart intervention — that has implications for TAVR, TEER, and TTVR procedures where cumulative radiation exposure to operators and patients is increasingly scrutinized. Results expected by late 2026.

---

Industry & Market

Edwards Lifesciences: Insider Sale and Analyst Momentum

Edwards Lifesciences CVP Daniel Lippis sold 1,019 shares ($82,522) under a pre-arranged 10b5-1 trading plan. The sale is routine and modest relative to institutional positions, but coincides with growing analyst attention to Edwards' tricuspid pipeline. GuruFocus reports that an analyst maintained coverage on EW with an unchanged target, while SimplyWallSt published a valuation analysis examining Edwards' positioning after EVOQUE TRISCEND II results and growing regulatory momentum in the tricuspid space.

UPMC Cardiologist Lawsuit

PennLive reports that UPMC fired a cardiologist who allegedly reported racist texts and a CEO's conflict of interest. While not directly a structural heart story, UPMC is a major cardiac surgery and transcatheter valve center; institutional governance issues at high-volume heart programs merit attention.

---

Financial Analysis

This week's tricuspid pipeline developments — TriCares' IDE approval and VDyne's pivotal trial clearance — frame the competitive dynamics heading into earnings season. Edwards Lifesciences, which reports Q1 earnings on April 22, holds the most advanced position in transcatheter tricuspid replacement through EVOQUE (TRISCEND II: 864 patients enrolled, actively not recruiting). But the rapid emergence of TriCares and VDyne as funded competitors introduces long-term market share uncertainty in what was previously a two-horse race between Edwards (replacement) and Abbott (TriClip repair). The tricuspid addressable market is estimated at $2–5B annually, but actual penetration remains early-stage, dependent on operator adoption and reimbursement frameworks that lag behind the ESC 2025 Class IIa recommendation.

Edwards trades at $81.19 with a forward P/E of 24.5 — a premium to Medtronic (14.2) and Abbott (16.8) that reflects the market's belief in Edwards' transcatheter growth runway. However, the 27-analyst consensus target of $96.93 implies 19% upside, suggesting Wall Street views the current price as a reasonable entry point. The insider sale by CVP Lippis ($82K under a 10b5-1 plan) is immaterial.

Abbott ($102.30) and Boston Scientific ($62.59) have experienced significant 6-month declines of 22% and 35% respectively, likely reflecting broader medtech headwinds including tariff concerns and macroeconomic uncertainty rather than structural heart-specific issues. Both report in mid-to-late April. Abbott's TriClip post-approval study in Japan (now recruiting 250 patients) signals ongoing geographic expansion, but the key commercial question — whether tricuspid TEER reimbursement will scale — depends on payer response to the TRILUMINATE and Tri.Fr data that underpinned the ESC upgrade.

---

Valve Industry Stocks

Edwards Lifesciences (EW)

• Close: $81.19 | Daily Change: +$0.14 (+0.17%)
• 6-Month Performance: +5.83% ($76.72 → $81.19)
• Market Cap: $47.2B | P/E (trailing): 44.86 | P/E (forward): 24.52
• Beta: 0.94 | 52-Week Range: $65.94 – $87.89
• Analyst Consensus: Buy | Target: $96.93 (range: $84 – $110, 27 analysts)
• Next Earnings: April 22, 2026 | EPS est: $0.73 | Revenue est: $1.60B
• Commentary: Edwards enters earnings week with EVOQUE/TRISCEND II momentum and growing regulatory traction in the tricuspid space. The stock has modestly outperformed over 6 months (+5.8%) in an otherwise weak medtech tape. The forward P/E of 24.5 is elevated but defensible if TAVR volumes remain robust and EVOQUE reimbursement scales. Watch for commentary on early commercial Evoque uptake and PASCAL enrollment progress. Multiple analyst reports this week maintained Buy ratings.

Medtronic (MDT)

• Close: $86.28 | Daily Change: -$0.35 (-0.40%)
• 6-Month Performance: -10.89% ($96.82 → $86.28)
• Market Cap: $110.8B | P/E (trailing): 24.10 | P/E (forward): 14.23
• Beta: 0.76 | 52-Week Range: $79.55 – $106.33
• Analyst Consensus: Buy | Target: $110.60 (range: $91 – $125, 25 analysts)
• Next Earnings: May 20, 2026 | EPS est: $1.54 | Revenue est: $9.65B
• Commentary: Medtronic has underperformed the sector over 6 months, trading near its 52-week low. The Evolut Low Risk long-term follow-up trial (NCT02701283, 2,223 patients) continues to generate durability data critical for maintaining market share vs. Edwards' SAPIEN. The Intrepid TMVR system (APOLLO trial, NCT03242642, recruiting with 1,056 patients) represents Medtronic's mitral bet. The forward P/E of 14.2 reflects the company's diversified (non-valve-dominated) revenue mix, but the analyst consensus target implies 28% upside.

Abbott (ABT)

• Close: $102.30 | Daily Change: -$0.57 (-0.55%)
• 6-Month Performance: -22.36% ($131.76 → $102.30)
• Market Cap: $177.8B | P/E (trailing): 27.50 | P/E (forward): 16.76
• Beta: 0.78 | 52-Week Range: $100.88 – $139.06
• Analyst Consensus: Buy | Target: $132.28 (range: $113 – $158, 25 analysts)
• Next Earnings: April 16, 2026 | EPS est: $1.15 | Revenue est: $11.00B
• Commentary: Abbott trades near its 52-week low following a sharp 22% decline over 6 months. The structural heart division (MitraClip, TriClip) faces competitive pressure from Edwards' PASCAL and EVOQUE platforms. The TriClip Japan Post-Approval Study (NCT07509658, 250 patients) signals geographic expansion, and TRILUMINATE long-term data continue to support the ESC 2025 Class IIa tricuspid recommendation. However, Abbott's near-term catalyst is Q1 earnings on April 16 — the first major medtech report of the season. The analyst target of $132.28 implies 29% upside from current levels, suggesting the selloff may be overdone.

Boston Scientific (BSX)

• Close: $62.59 | Daily Change: -$0.23 (-0.37%)
• 6-Month Performance: -34.73% ($95.90 → $62.59)
• Market Cap: $93.0B | P/E (trailing): 32.26 | P/E (forward): 16.01
• Beta: 0.78 | 52-Week Range: $61.25 – $109.50
• Analyst Consensus: Strong Buy | Target: $100.81 (range: $83 – $124, 32 analysts)
• Next Earnings: April 22, 2026 | EPS est: $0.79 | Revenue est: $5.18B
• Commentary: BSX has been the worst performer in the group, declining nearly 35% over 6 months to trade near its 52-week low of $61.25. Despite the Strong Buy consensus from 32 analysts and an implied 61% upside to the $100.81 target, the stock reflects broader medtech risk-off sentiment. Boston Scientific's structural heart exposure is smaller than peers but includes the ACURATE neo2 TAVR system (European market) and the investigational WATCHMAN FLX for LAA closure. Earnings on April 22 will be closely watched alongside Edwards.

Anteris Technologies (AVR.AX)

• Close: A$7.55 | Daily Change: Flat
• 6-Month Performance: +17.05% (A$6.45 → A$7.55)
• Market Cap: A$0.8B | P/E (forward): -3.46 (pre-revenue)
• Beta: 0.55 | 52-Week Range: A$4.26 – A$9.79
• Analyst Target: A$13.00 (1 analyst)
• Commentary: Anteris, developer of the DurAVR single-piece tissue TAVR valve, remains a speculative small-cap with the best 6-month performance in the group (+17%). The pre-revenue company is advancing its novel valve concept, which uses a single piece of bovine pericardium to potentially improve hemodynamics and durability. Extremely low trading volume (1,214 shares) limits price reliability.

Private Companies: JenaValve Technology (Trilogy system, ALIGN-AR LVAD Registry recruiting), J Valve Technology, and Meril Life Sciences (Myval platform, featured in the LANDMARK trial) remain private with no public stock data available. JenaValve's ALIGN-AR registry (NCT06594705, 50 patients) represents the most advanced transcatheter pure AR program — a space where the ESC 2025 guidelines now provide a Class IIb recommendation for inoperable patients.

Market Outlook: The medtech sector enters a critical two-week earnings window with Abbott (April 16), Edwards and Boston Scientific (both April 22), and Medtronic (May 20). All four major valve companies trade well below analyst consensus targets, suggesting either significant upside potential or downward target revisions ahead. The fundamental story — expanding transcatheter indications, ESC 2025 guideline upgrades for TEER and tricuspid therapies, and the TAVI age threshold shift — supports long-term structural heart growth. But near-term headwinds (tariff uncertainty, healthcare spending caution, rate sensitivity) have compressed multiples. Watch for forward guidance on TAVR procedure volumes, EVOQUE launch metrics, and any commentary on the impact of the ESC 2025 guideline changes on European adoption rates.

---

Clinical Trial Updates

Aortic Valve

• [LANDMARK] Evolut Low Risk — Long-Term Follow-Up (NCT02701283)
  • Status: Active, not recruiting | Enrollment: 2,223 | Sponsor: Medtronic Cardiovascular
  • This pivotal trial comparing the Evolut self-expanding TAVR system to SAVR in low-risk patients continues to generate the long-term durability data that both the ACC/AHA 2020 and ESC 2025 guidelines reference. The ESC shifted its TAVI-preferred threshold to age ≥70 partly based on these data, though robust follow-up beyond 5–7 years remains limited. Updated March 2026.
• REdo TAVI for Management of Transcatheter Aortic Valve Failure (NCT06557798)
  • Status: Recruiting | Enrollment: 550 | Sponsor: Leeds Teaching Hospitals NHS Trust
  • Three-arm trial comparing redo-TAVI (TAV-in-TAV), surgical explant, and conservative management. Addresses the ESC 2025 emphasis on lifetime management planning. Critical data needed as redo-TAVI accounts for 84% of TAVR reinterventions. Updated April 2026.
• PRessure-based Evaluation of Disease Improvement in the Course of TAVI (PREDICT) (NCT07509554)
  • Status: Not yet recruiting | Enrollment: 100 | Sponsor: Istanbul Mehmet Akif Ersoy Hospital
  • Hemodynamic assessment study. Updated April 2026.
• Conduction System vs. Right Ventricular Pacing Post-TAVI (NCT06197503)
  • Status: Recruiting | Enrollment: 48 | Sponsor: Hospital Clinic of Barcelona
  • Randomized study of physiological vs. RV pacing in patients with normal ventricular function requiring pacing after TAVI — an important question given that new pacemaker implantation remains one of TAVR's most common complications (10–20% with self-expanding valves). Updated March 2026.
• JenaValve ALIGN-AR LVAD Registry (NCT06594705)
  • Status: Recruiting | Enrollment: 50 | Sponsor: JenaValve Technology
  • Evaluating the Trilogy Heart Valve System for aortic regurgitation in LVAD patients — a niche but underserved population. ESC 2025 provides Class IIb for TAVI in AR for inoperable patients. Updated April 2026.
• Preoperative Dental Screening Before Valve Surgery/TAVI (NCT07511673)
  • Status: Not yet recruiting | Enrollment: 1,300 | Sponsor: Region Skane
  • RCT testing whether preoperative dental screening improves outcomes in patients undergoing surgical or transcatheter valve procedures — relevant to infective endocarditis prevention. Updated April 2026.

Mitral Repair (TEER)

• [LANDMARK] REPAIR-MR — MitraClip vs. Surgery for Primary MR (NCT04198870)
  • Status: Active, not recruiting | Enrollment: 500 | Sponsor: Abbott Medical Devices
  • This pivotal head-to-head trial comparing MitraClip to surgical MV repair in primary MR is one of the most anticipated studies in structural heart. Both ACC/AHA and ESC guidelines currently rate TEER as IIa (subordinate to surgery) for primary MR — REPAIR-MR could change this paradigm. Last updated November 2025.
• [LANDMARK] PRIMATY — MitraClip vs. Medical Therapy for Secondary MR (NCT05051033)
  • Status: Recruiting | Enrollment: 450 | Sponsor: Annetine Gelijns
  • Testing whether TEER benefit extends to a broader SMR population beyond strict COAPT criteria. Compares mitral valve repair vs. TEER — important for defining the appropriate role of transcatheter therapy when the ESC has now upgraded TEER for ventricular SMR to Class I. Updated March 2026.
• [LANDMARK] COAPT — Long-Term Follow-Up (NCT03706833)
  • Status: Active, not recruiting | Enrollment: 1,247 | Sponsor: Edwards Lifesciences
  • The trial that transformed SMR treatment — now in extended follow-up with PASCAL system included. The 5-year data confirming sustained benefit drove the ESC 2025 upgrade to Class I. Updated February 2026.
• Edwards PASCAL Pivotal Trial (NCT04097145)
  • Status: Recruiting | Enrollment: 870 | Sponsor: Edwards Lifesciences
  • Testing the PASCAL TEER system vs. optimal medical therapy. Critical for Edwards' competitive positioning against Abbott's MitraClip in both primary and secondary MR. Updated April 2026.

Mitral Replacement (TMVR)

• Medtronic Intrepid TMVR System (APOLLO) (NCT03242642)
  • Status: Recruiting | Enrollment: 1,056 | Sponsor: Medtronic Cardiovascular
  • The largest TMVR trial in progress, evaluating the Intrepid system for severe symptomatic MR. TMVR remains earlier stage than TEER, with both guidelines positioning it as investigational or for high/prohibitive-risk patients. Updated March 2026.

Tricuspid Repair

• [LANDMARK] TRILUMINATE Pivotal — TriClip for TR (NCT03904147)
  • Status: Active, not recruiting | Enrollment: 572 | Sponsor: Abbott Medical Devices
  • The landmark trial that (along with Tri.Fr and TRISCEND II) drove the ESC 2025 Class IIa recommendation for transcatheter TR treatment. Two-year data showed reduced composite endpoint driven by QoL improvement and HF hospitalization reduction. Last updated December 2024.
• TriClip Japan Post-Approval Study (NCT07509658)
  • Status: Recruiting | Enrollment: 250 | Sponsor: Abbott Medical Devices
  • Post-market surveillance for TriClip in Japan — an important geographic expansion market for tricuspid TEER. Updated April 2026.

Tricuspid Replacement

• [LANDMARK] TRISCEND II — Evoque Tricuspid Replacement (NCT04482062)
  • Status: Active, not recruiting | Enrollment: 864 | Sponsor: Edwards Lifesciences
  • The pivotal trial for Edwards' Evoque TTVR system, which showed superior symptom/QoL improvement vs. medical therapy but with higher bleeding and pacemaker rates. One of three trials driving the ESC 2025 tricuspid recommendation. Updated February 2026.
• VISTA-US — VDyne Tricuspid Valve Replacement (NCT05848284)
  • Status: Recruiting | Phase: Early feasibility | Enrollment: 30 | Sponsor: VDyne, Inc.
  • [NOTABLE — Status: now actively recruiting after FDA pivotal trial clearance this week.] Early-stage but the FDA nod to proceed signals regulatory confidence. Updated March 2026.

Other Relevant Trials

• NHLBI-Emory Advanced Cardiac CT Reconstruction (NCT05372627)
  • Status: Not yet recruiting | Enrollment: 1,000 | Sponsor: NHLBI
  • Advanced CT imaging reconstruction study with potential applications for pre-procedural TAVR planning and valve assessment. Updated April 2026.
• Losartan in Prevention of Radiation-Induced Heart Failure (NCT05607017)
  • Status: Completed | Phase: Early Phase 1 | Enrollment: 5 | Sponsor: Massachusetts General Hospital
  • Small pilot completed. Radiation-induced heart disease is a growing TAVR indication — patients with prior chest radiation are guideline-recognized as TAVI-favored. Updated April 2026.

---

Social & Conference Highlights

No major conference presentations or notable social media discussions identified today. The next major structural heart meeting to watch is EuroPCR (May 2026), where updated data from several trials highlighted above may be presented.

---

Looking Ahead: All eyes turn to earnings season — Abbott reports April 16, followed by Edwards Lifesciences and Boston Scientific on April 22. With all three trading near 52-week lows and structural heart volumes presumably robust, forward guidance will be the key differentiator. On the clinical front, the twin FDA clearances for tricuspid replacement trials (TriCares IDE + VDyne pivotal) signal that the regulatory pathway for TTVR is maturing, but the field awaits head-to-head data against TEER to determine which patients benefit most from repair vs. replacement. The ESC 2025 guidelines opened the door; the trials now need to walk through it.

— E. Nolan Beckett | The Valve Wire